Berberis lycium (Berberis lycium): Benefits, Dosage, Safety & Evidence

Frequently asked questions

How does Berberis lycium work in the body?

Berberis lycium exerts its medicinal effects primarily through berberine, its main active alkaloid. Berberine works by activating AMP-activated protein kinase (AMPK), an enzyme that regulates metabolism, which explains its blood sugar-lowering effects. The plant's alkaloids, including berbamine and palmatine, demonstrate antimicrobial activity by disrupting bacterial cell membranes and inhibiting enzyme function. Tannins provide astringent properties that help reduce inflammation and promote tissue healing. These combined mechanisms support its traditional use for infections, diabetes, and inflammatory conditions. Evidence Level C.

Does Berberis lycium interact with diabetes medications?

Yes, Berberis lycium can interact with diabetes medications due to its berberine content, which has glucose-lowering properties. When combined with antidiabetic drugs like metformin, sulfonylureas, or insulin, it may cause additive effects leading to hypoglycemia (dangerously low blood sugar). Patients taking diabetes medications should monitor blood glucose closely and consult a healthcare provider before using Berberis lycium. Dosage adjustments to prescription medications may be necessary. This interaction is supported by pharmacological evidence at Level C.

What is the recommended dosage for Berberis lycium?

The typical adult dosage for Berberis lycium extract is 500mg taken twice daily. For external use, the bark paste known as Rasaut can be applied locally or used as a diluted eye wash for conjunctivitis and eye infections. Standardized extracts are preferred for consistent berberine content. Dosage should be started low and gradually increased to assess tolerance. There is insufficient evidence to establish safe pediatric dosing. Always follow product-specific recommendations or consult a qualified herbalist. Evidence Level C.

Is Berberis lycium safe during pregnancy?

No, Berberis lycium is contraindicated during pregnancy and breastfeeding. The berberine content can stimulate uterine contractions and may cross the placenta, potentially causing harm to fetal development. Berberine has been shown to inhibit bilirubin clearance, posing risks to newborns. This herb should also be avoided by nursing mothers as compounds can pass into breast milk. Women attempting to conceive should discontinue use. These safety concerns are supported by traditional knowledge and pharmacological evidence at Level C.

Can Berberis lycium treat eye infections and conjunctivitis?

Berberis lycium has a long history of traditional use in Unani medicine for treating eye infections and conjunctivitis. The bark paste, called Rasaut, is applied externally around the eyes or used as a diluted eye wash. Berberine demonstrates antimicrobial and anti-inflammatory properties that may help combat bacterial infections and reduce inflammation. However, clinical evidence remains limited (Level C). Eye infections require proper medical diagnosis, as untreated conditions can lead to serious complications. Consult an eye care professional before using herbal preparations in or around the eyes.

What are the side effects of Berberis lycium?

Common side effects of Berberis lycium include gastrointestinal upset such as nausea, vomiting, diarrhea, and stomach cramps, particularly when taken at higher doses. Hypoglycemia (low blood sugar) can occur, especially in people with diabetes or those taking blood sugar-lowering medications. The herb is contraindicated in pregnancy, breastfeeding, and in neonates due to risks of bilirubin displacement and uterine stimulation. Long-term safety data is limited. Discontinue use if adverse effects occur and seek medical attention for severe reactions. Evidence Level C.

PubMed-compiled information sheet

This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.

Compiled from 30 PubMed articles · model: gemma4:31b

Summary

Berberis lycium (B. lycium) is a wild shrub native to the Himalayas and subtropical regions of Asia, recognized for its diverse bioactive compounds and therapeutic potential [PMID: 40302071, PMID: 32787584].

Background

Also known as barberry, Kashmal, or Simbulu, B. lycium is a member of the Berberidaceae family that grows wildly in the Himalayas and regions of Pakistan and India [PMID: 40302071, PMID: 27162400, PMID: 32787584].

Traditional uses

Traditionally used to treat diabetes, arthritis, joint pain, stomach ulcers, diarrhea, abdominal spasms, coughs, chest problems, rheumatism, eye and ear diseases, malarial fever, and skin diseases [PMID: 34616483, PMID: 36587881, PMID: 32617102].

Active compounds

Principal bioactive compounds include berberine and oxyberberine [PMID: 39072259, PMID: 32617102]. The berries contain anthocyanins, specifically delphinidin-3-glucoside and cyanidin-3-glucoside, as well as phenolics like chlorogenic acid and coumaric acid [PMID: 27162400]. Other identified constituents include rutin and $\beta$-sitosterol [PMID: 35254584, PMID: 32617102].

Mechanism of action

B. lycium extracts may mitigate oxi-inflammatory stress by suppressing the NF-$\kappa$B/MAPK signaling cascade and augmenting splenic Treg proliferation [PMID: 30520005, PMID: 31620885]. In arthritis models, it is reported to improve the GSK3$\beta$/STAT/Akt/MAPKs/NF-$\kappa$B signaling axis [PMID: 35254584]. Computational studies suggest potential inhibition of SARS-CoV-2 and influenza RNA-dependent RNA polymerase (RdRP) and dengue virus enzymes [PMID: 39072259].

Clinical evidence

Evidence DUlcerative Colitis (Murine Model)

Fruit extract (BLFE) improved survival rate, colon length, and structural damage while mitigating NF-$\kappa$B/c-Jun/MAPKs signaling [PMID: 31620885]

Evidence DRheumatoid Arthritis (Murine Model)

Fruit extract, berberine, and rutin mitigated disease severity index, articular damage, and immune cell influx [PMID: 35254584]

Evidence DDiabetes (Rat Model)

Methanolic extracts exhibited anti-hyperglycemic effects in alloxan-induced diabetic rats and inhibited alpha-amylase in vitro [PMID: 33612464]

Evidence BNephrotoxicity (Rat Model)

Aqueous root bark extract (400 mg/kg) was evaluated for reno-protective roles against gentamicin-induced toxicity [PMID: 35124906]

Evidence DHepatocarcinoma (In Vitro)

Water/ethanolic extracts exhibited antiproliferative activity against HepG2 cells (IC50 47 $\mu$g/mL) by inducing apoptosis [PMID: 33110920]

Evidence DBacterial Infections (In Vitro/In Vivo)

Safety & adverse effects

No obvious toxic effects were noted for plant extracts up to doses of 1.6 g/kg in rabbits [PMID: 3878916]. Computational analysis of berberine and oxyberberine indicated a non-toxic profile [PMID: 39072259].

Evidence summary

The evidence consists primarily of in vitro studies, animal models (rats/mice), and a single case report. There is a lack of high-level human clinical trials (RCTs or meta-analyses) to confirm therapeutic efficacy in humans.

PubMed sources

1.PMID: 39072259 (2024) — Computational Exploration of Berberis lycium Royle: A Hidden Treasure Trove for Antiviral Development. · Bioinformatics and biology insights
2.PMID: 17583443 (2007) — Antimicrobial activities of Indian Berberis species. · Fitoterapia
3.PMID: 40302071 (2025) — Berberis lycium: A Natural Source of Antioxidants and Bioactive Compounds. · Asian Pacific journal of cancer prevention : APJCP
4.PMID: 27162400 (2016) — Anthocyanin profiling of Berberis lycium Royle berry and its bioactivity evaluation for its nutraceutical potential. · Journal of food science and technology
5.PMID: 42251808 (2026) — Management of multinodular goitre: Significant nodular regression and avoidance of thyroidectomy-a case report. · Explore (New York, N.Y.)

Berberis lycium

Sources & Citations

Calculate a safe dose of Berberis lycium